Delcath Systems (DCTH) to Release Quarterly Earnings on Friday

Delcath Systems (NASDAQ:DCTH - Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Delcath Systems to post earnings of ($0.21) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.12). The business had revenue of $7.77 million during the quarter, compared to analyst estimates of $5.00 million. Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. During the same quarter last year, the company posted ($0.58) EPS. On average, analysts expect Delcath Systems to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Delcath Systems Stock Down 3.6 %

Shares of NASDAQ DCTH traded down $0.39 during midday trading on Friday, reaching $10.50. 265,491 shares of the stock were exchanged, compared to its average volume of 263,827. The firm has a market cap of $291.80 million, a price-to-earnings ratio of -4.12 and a beta of 0.78. Delcath Systems has a twelve month low of $2.25 and a twelve month high of $11.74. The firm has a 50-day simple moving average of $9.68 and a two-hundred day simple moving average of $8.07.

Analysts Set New Price Targets

A number of brokerages have recently commented on DCTH. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. Stephens reaffirmed a "buy" rating on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com raised shares of Delcath Systems from a "sell" rating to a "hold" rating in a research note on Friday, October 25th. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and set a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.